Geneos Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Geneos Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-119	Closed	-$13.5K	–	2876
2025 Q2	$13.5K	Sell	119 -180	-60%	-$19.2K	﹤0.01%	2201
2025 Q1	$31.4K	Buy	299 +238	+390%	+$26.9K	﹤0.01%	2129
2024 Q4	$6.54K	Hold	61	–	–	﹤0.01%	2222
2024 Q3	$6.11K	Buy	+61	New	+$6.14K	﹤0.01%	2008
2019 Q4	–	Sell	-22	Closed	-$1K	–	2563
2019 Q3	$1K	Hold	22	–	–	﹤0.01%	2415
2019 Q2	$1K	Buy	+22	New	+$1.62K	﹤0.01%	2415
2018 Q4	–	Sell	-152	Closed	-$26K	–	2441
2018 Q3	$26K	Hold	152	–	–	﹤0.01%	1460
2018 Q2	$19K	Buy	+152	New	+$17K	﹤0.01%	1471

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geneos Wealth Management's LGND Position: Q3 2025 in Review

Geneos Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2025, closing a stake of 119 shares — an estimated $13.5K sold.

Geneos Wealth Management first reported a position in LGND in Q2 2018 and held it in 8 quarters. The position peaked at $31.4K in Q1 2025. 314 funds tracked by Wall St. Rank hold LGND as of Q3 2025.

Geneos Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Geneos Wealth Management sold 119 Ligand Pharmaceuticals shares in Q3 2025, an estimated $13.5K.
Geneos Wealth Management first reported a position in Ligand Pharmaceuticals in Q2 2018 and held it in 8 quarters.
Geneos Wealth Management's Ligand Pharmaceuticals position peaked at $31.4K in Q1 2025.
314 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.